Importantly, analyses of human plasma and cerebrospinal fluid in their study without preventing heterophilic antibody interferences were likely to cause false positive results and obscure the obtained data.27 Overall, the results of both studies suggest technical and methodological improvements in order to use Trx1 as a biological marker for BPD. The gene discussed is TXN; the disease is bronchopulmonary dysplasia.